CA2303598C - Dosage immunologique en tandem pour diagnostiquer le cancer - Google Patents

Dosage immunologique en tandem pour diagnostiquer le cancer Download PDF

Info

Publication number
CA2303598C
CA2303598C CA 2303598 CA2303598A CA2303598C CA 2303598 C CA2303598 C CA 2303598C CA 2303598 CA2303598 CA 2303598 CA 2303598 A CA2303598 A CA 2303598A CA 2303598 C CA2303598 C CA 2303598C
Authority
CA
Canada
Prior art keywords
ndp
kinase
lapase
cells
breast cancer
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Expired - Fee Related
Application number
CA 2303598
Other languages
English (en)
Other versions
CA2303598A1 (fr
Inventor
Gabriel Pulido-Cejudo
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Canbreal Therodiagnostics Canada Holding Corp
Canada Minister of Health
Original Assignee
Canbreal Therodiagnostics Canada Holding Corp
Canada Minister of Health
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Priority claimed from CA002267481A external-priority patent/CA2267481A1/fr
Application filed by Canbreal Therodiagnostics Canada Holding Corp, Canada Minister of Health filed Critical Canbreal Therodiagnostics Canada Holding Corp
Priority to CA 2303598 priority Critical patent/CA2303598C/fr
Publication of CA2303598A1 publication Critical patent/CA2303598A1/fr
Application granted granted Critical
Publication of CA2303598C publication Critical patent/CA2303598C/fr
Anticipated expiration legal-status Critical
Expired - Fee Related legal-status Critical Current

Links

Classifications

    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/53—Immunoassay; Biospecific binding assay; Materials therefor
    • G01N33/569—Immunoassay; Biospecific binding assay; Materials therefor for microorganisms, e.g. protozoa, bacteria, viruses
    • G01N33/56983—Viruses
    • G01N33/56988—HIV or HTLV
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/40—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against enzymes
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
    • C12Q1/00—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions
    • C12Q1/34—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions involving hydrolase
    • C12Q1/37—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions involving hydrolase involving peptidase or proteinase
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/53—Immunoassay; Biospecific binding assay; Materials therefor
    • G01N33/574—Immunoassay; Biospecific binding assay; Materials therefor for cancer
    • G01N33/57407—Specifically defined cancers
    • G01N33/57415—Specifically defined cancers of breast
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Immunology (AREA)
  • Engineering & Computer Science (AREA)
  • Molecular Biology (AREA)
  • Organic Chemistry (AREA)
  • Biochemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Hematology (AREA)
  • Urology & Nephrology (AREA)
  • Biomedical Technology (AREA)
  • Microbiology (AREA)
  • Biotechnology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Medicinal Chemistry (AREA)
  • Physics & Mathematics (AREA)
  • Analytical Chemistry (AREA)
  • Biophysics (AREA)
  • Virology (AREA)
  • General Physics & Mathematics (AREA)
  • Pathology (AREA)
  • Cell Biology (AREA)
  • Food Science & Technology (AREA)
  • Genetics & Genomics (AREA)
  • Wood Science & Technology (AREA)
  • Zoology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • General Engineering & Computer Science (AREA)
  • Hospice & Palliative Care (AREA)
  • AIDS & HIV (AREA)
  • Oncology (AREA)
  • Tropical Medicine & Parasitology (AREA)
  • Investigating Or Analysing Biological Materials (AREA)
  • Peptides Or Proteins (AREA)
  • Preparation Of Compounds By Using Micro-Organisms (AREA)
CA 2303598 1999-03-30 2000-03-30 Dosage immunologique en tandem pour diagnostiquer le cancer Expired - Fee Related CA2303598C (fr)

Priority Applications (1)

Application Number Priority Date Filing Date Title
CA 2303598 CA2303598C (fr) 1999-03-30 2000-03-30 Dosage immunologique en tandem pour diagnostiquer le cancer

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
CA002267481A CA2267481A1 (fr) 1999-03-30 1999-03-30 Interdependance critique : du role de l'oestrogene dans le cancer du sein a la sensibilite des femmes a l'infection par le vih
CA2,267,481 1999-03-30
CA 2303598 CA2303598C (fr) 1999-03-30 2000-03-30 Dosage immunologique en tandem pour diagnostiquer le cancer

Publications (2)

Publication Number Publication Date
CA2303598A1 CA2303598A1 (fr) 2000-09-11
CA2303598C true CA2303598C (fr) 2002-07-23

Family

ID=25680866

Family Applications (1)

Application Number Title Priority Date Filing Date
CA 2303598 Expired - Fee Related CA2303598C (fr) 1999-03-30 2000-03-30 Dosage immunologique en tandem pour diagnostiquer le cancer

Country Status (1)

Country Link
CA (1) CA2303598C (fr)

Also Published As

Publication number Publication date
CA2303598A1 (fr) 2000-09-11

Similar Documents

Publication Publication Date Title
US6521415B1 (en) Tandem immuno-assay for cancer
JPH06317589A (ja) アッセイ干渉を排除したイムノアッセイ法およびキット
US20130260388A1 (en) Blood markers for diagnosing epithelium derived cancers and monoclonal antibodies thereof
Schwartz et al. Monitoring therapy by serum HER-2/neu
AU601455B2 (en) Method of detecting or estimating biological material
CN108398566A (zh) 一种基于量子点微球的荧光免疫层析检测卡及其制备方法
CN108780095A (zh) 利用简易免疫测定的癌胚纤连蛋白检测方法
JP2000095799A (ja) 抗体のフレ―ムワ―ク領域から誘導される物質によるイムノアッセイの干渉の減少
CN107271674B (zh) 一种用于脂肪性肝炎检测的靶标志物gp73及检测应用方法
KR20090040118A (ko) 허셉틴을 이용한 유방암 진단 키트, 조성물 및 이들을이용하여 허셉틴 민감성 ｈｅｒ２ 과발현 세포를 검출하는방법
EP2707720B1 (fr) Diagnostic et pronostic de cancer du sein triple-négatif et de l'ovaire
EP1172654B1 (fr) Méthode de diagnostique de tumeurs ovariennes et endométriales basée sur la détection de la molécule d'adhésion L1
CA2303598C (fr) Dosage immunologique en tandem pour diagnostiquer le cancer
JPH0580053A (ja) ヒト子宮体癌細胞の免疫化学的検出方法
CA2303505C (fr) Anticorps monoclonal anti-leucine aminopeptidase stimulee par l'oestrogene
Kim et al. Monoclonal antibody PR92 with restricted specificity for tumor-associated antigen of prostate and breast carcinoma
KR20070059373A (ko) Ｎｄｒｇ2 단백질에 대한 단일클론항체 및 단백질 칩을이용한 정량 측정법
EP1604032A2 (fr) Methode permettant de determiner le pronostic d'un cancer
KR101219505B1 (ko) 고양이 톡소포자충 감염 진단 방법 및 키트
CN115651914A (zh) 杂交瘤细胞、单克隆抗体和p4hb蛋白检测试剂
KR20080028642A (ko) 유방암 진단용 단백질 마커 엔도레펠린 ｌｇ3 절편 및 이에대한 항체를 포함하는 유방암 진단키트
KR20210130049A (ko) 라싸 바이러스 핵단백질에 특이적인 항체, 이를 생산하는 하이브리도마 세포주 및 이를 이용한 라싸 바이러스 검출 키트
CN117946244A (zh) 一种cd73蛋白的检测方法、试剂盒及其应用
Vengerov et al. Immunochemical studies of human placental alkaline phosphatase in normal and neoplastic tissues
CN116381245A (zh) 光激化学发光检测cea的试剂组合、试剂盒及其应用

Legal Events

Date Code Title Description
EEER Examination request
MKLA Lapsed